TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
MISSION THERAPEUTICS LIMITED
US Patent
MISSION THERAPEUTICS LIMITED
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
